This summary was created by AI, based on 1 opinions in the last 12 months.
Owens & Minor (OMI-N) has been identified as a top pick in smallcap health, showing impressive growth during the Covid pandemic. The company's acquisition of two companies in home healthcare contributed to a sales rise of 24% in 2023, and they have projected annual EPS growth of 20%. Despite a decline in PPP, the overall outlook for OMI-N appears positive, with a focus on expansion and steady financial performance.
Owens & Minor is a American stock, trading under the symbol OMI-N on the New York Stock Exchange (OMI). It is usually referred to as NYSE:OMI or OMI-N
In the last year, 1 stock analyst published opinions about OMI-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Owens & Minor.
Owens & Minor was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Owens & Minor.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Owens & Minor published on Stockchase.
On 2024-04-25, Owens & Minor (OMI-N) stock closed at a price of $24.12.
A top pick in smallcap health. They made PPP during Covid then bought two companies in home healthcare. Sales rose 24% in 2023, though PPP declined. They just projected EPS growing 20% annually.